ArticleInternational journal of bipolar disorders2026
Views on an antipsychotic regimen administered once every 2 months: a qualitative interview study of people living with bipolar I disorder, caregivers, and prescribers in the USA and Canada.
Article in International journal of bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on factors that influence patient and caregiver preference for long-acting injectable (LAI) formulations of antipsychotics are limited in bipolar I disorder (BP-I), particularly regarding longer dosing intervals. The objective of this study was to explore healthcare experiences, preferences for LAI dosing frequency, and factors influencing preferences for a hypothetical LAI administered once every 2 months, in people living with BP-I, caregivers, and prescribers.
methodsThis qualitative interview study recruited people living with BP-I currently treated with a once-monthly LAI, caregivers, and prescribers from the USA and Canada. In semi-structured interviews, participants were asked about their treatment experiences, views on an ideal treatment, and preferences on LAI dosing frequency. Interview transcripts were analyzed descriptively for key themes.
resultsTwelve people living with BP-I currently treated with a once-monthly LAI, five caregivers, and five prescribers were interviewed. All three participant groups perceived frequency of administration and remaining on the same antipsychotic as key features of an LAI; prescribers also considered previous responses to treatment, treatment access, and the need to maintain control of medication important when prescribing. Participants were positive about an LAI administered once every 2 months compared with LAIs in general due to improved convenience, reduced patient and caregiver impact, and the potential to feel well and stable for longer.
conclusionsParticipants were positive about a potential transition to an LAI given once every 2 months. As each participant group has unique preferences for LAIs and treatment goals, these should be discussed during healthcare interactions to ensure that targeted disease management goals are met.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.